JP2006527264A5 - - Google Patents

Download PDF

Info

Publication number
JP2006527264A5
JP2006527264A5 JP2006516839A JP2006516839A JP2006527264A5 JP 2006527264 A5 JP2006527264 A5 JP 2006527264A5 JP 2006516839 A JP2006516839 A JP 2006516839A JP 2006516839 A JP2006516839 A JP 2006516839A JP 2006527264 A5 JP2006527264 A5 JP 2006527264A5
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
hydrogen atom
formula
lower alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006516839A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006527264A (ja
JP4778894B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2004/008486 external-priority patent/WO2004108137A1/en
Publication of JP2006527264A publication Critical patent/JP2006527264A/ja
Publication of JP2006527264A5 publication Critical patent/JP2006527264A5/ja
Application granted granted Critical
Publication of JP4778894B2 publication Critical patent/JP4778894B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006516839A 2003-06-10 2004-06-10 不安障害の治療方法 Expired - Fee Related JP4778894B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US50904603P 2003-06-10 2003-06-10
US60/509,046 2003-06-10
US53279303P 2003-12-24 2003-12-24
US60/532,793 2003-12-24
PCT/JP2004/008486 WO2004108137A1 (en) 2003-06-10 2004-06-10 A method of treating an anxiety disorder

Publications (3)

Publication Number Publication Date
JP2006527264A JP2006527264A (ja) 2006-11-30
JP2006527264A5 true JP2006527264A5 (cg-RX-API-DMAC7.html) 2007-06-07
JP4778894B2 JP4778894B2 (ja) 2011-09-21

Family

ID=33514319

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006516839A Expired - Fee Related JP4778894B2 (ja) 2003-06-10 2004-06-10 不安障害の治療方法

Country Status (15)

Country Link
US (2) US8202869B2 (cg-RX-API-DMAC7.html)
EP (1) EP1631294B1 (cg-RX-API-DMAC7.html)
JP (1) JP4778894B2 (cg-RX-API-DMAC7.html)
KR (1) KR20060037252A (cg-RX-API-DMAC7.html)
CN (1) CN1787821A (cg-RX-API-DMAC7.html)
AT (1) ATE481101T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004244906A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0411120A (cg-RX-API-DMAC7.html)
CA (1) CA2528710C (cg-RX-API-DMAC7.html)
CO (1) CO5640121A2 (cg-RX-API-DMAC7.html)
DE (1) DE602004029160D1 (cg-RX-API-DMAC7.html)
EA (1) EA200501924A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA05013148A (cg-RX-API-DMAC7.html)
NO (1) NO20055907L (cg-RX-API-DMAC7.html)
WO (1) WO2004108137A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2716404T3 (es) * 2002-01-28 2019-06-12 Kyowa Hakko Kogyo Kk Antagonistas de receptores A2A para su uso en el tratamiento de trastornos del movimiento
US10042980B2 (en) 2005-11-17 2018-08-07 Gearbox Llc Providing assistance related to health
US10296720B2 (en) 2005-11-30 2019-05-21 Gearbox Llc Computational systems and methods related to nutraceuticals
US20070136092A1 (en) * 2005-11-30 2007-06-14 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational and/or control systems related to individualized pharmaceutical and nutraceutical selection and packaging
US20070124176A1 (en) * 2005-11-30 2007-05-31 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational and/or control systems and methods related to nutraceutical agent selection and dosing
US7994190B2 (en) 2006-11-01 2011-08-09 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
MX2010000938A (es) * 2007-07-23 2010-07-01 Synosia Therapeutics Inc Uso de (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)-amida del ácido 4-hidroxi-4-metil-piperidin-1-carboxílico para el tratamiento del trastorno por estrés postraumático.
UA113383C2 (xx) * 2009-09-02 2017-01-25 Терапевтичний агент для лікування тривожних розладів
UA110097C2 (uk) 2009-09-02 2015-11-25 Терапевтичний агент для лікування розладів настрою
US8609162B2 (en) * 2012-10-04 2013-12-17 Invivo Beverages Llc Integrated neuromodulation system for mood enhancement of a living human subject
CN105770563A (zh) * 2016-04-22 2016-07-20 孙建 一种治疗焦虑症的中药制剂及其制备方法
AU2019227607C1 (en) 2018-02-27 2023-07-20 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
EP3810610A1 (en) 2018-05-18 2021-04-28 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
CN117304191A (zh) 2018-07-05 2023-12-29 因赛特公司 作为a2a/a2b抑制剂的稠合吡嗪衍生物
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
WO2022167778A1 (en) 2021-02-02 2022-08-11 Haiku Therapeutics Ltd Ebselen as adenosine receptor modulator
KR102567684B1 (ko) 2023-01-10 2023-08-18 주식회사 웨이센 디지털 표현형 특징을 이용한 사회 불안장애 분석방법 및 장치
KR102594242B1 (ko) 2023-01-10 2023-10-27 주식회사 웨이센 디지털 표현형 특징을 이용한 사회 불안장애 분석방법 및 장치

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3781080T2 (de) * 1986-09-30 1992-12-24 Ciba Geigy Ag 2-substituierte-e-kondensierte(1,2,4)triazolo-(1,5-c)pyrimidine, pharmazeutische zubereitungen und ihre verwendung.
US5047534A (en) * 1990-03-26 1991-09-10 Merrell Dow Pharmaceuticals Inc. Selective adenosine receptor agents
US5484920A (en) 1992-04-08 1996-01-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for Parkinson's disease
JP2928386B2 (ja) * 1992-07-08 1999-08-03 協和醗酵工業株式会社 うつ病治療剤
ES2264210T3 (es) 1997-09-05 2006-12-16 Kyowa Hakko Kogyo Co., Ltd. Derivados de xantina para el tratamiento de la isquemia cerebral.
KR20010087361A (ko) 1998-09-22 2001-09-15 히라타 다다시 [1,2,4]트리아졸로[1,5-c]피리미딘 유도체
AR023966A1 (es) * 1999-05-12 2002-09-04 Fujisawa Pharmaceutical Co Una composicion farmaceutica para la prevencion y/o el tratamiento de la enfermedad de parkinson y los sintomas concomitantes de la misma, y el uso de unantagonista dual receptor de adenosina a1 a2a para preparar dicha composicion
PT1283839E (pt) * 2000-05-26 2005-08-31 Schering Corp Antagonistas do receptor a2a da adenosina
EP1425017A1 (en) * 2001-09-13 2004-06-09 Schering Corporation Combination of an adenosine a2a receptor antagonist and an antidepressant or anxiolytic
JP4545437B2 (ja) * 2001-10-15 2010-09-15 シェーリング コーポレイション アデノシンa2a受容体アンタゴニストとしてのイミダゾ(4,3−e)−1,2,4−トリアゾロ(1,5−c)ピリミジン
AU2002340405A1 (en) * 2001-11-20 2003-06-10 Bristol-Myers Squibb Pharma Company 3,7-dihydro-purine-2,6-dione derivatives as crf receptor ligands
US20060128694A1 (en) * 2002-12-19 2006-06-15 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders

Similar Documents

Publication Publication Date Title
JPH08259567A (ja) ピラゾロピリミジン類およびピロロピリミジン類によるニューロン疾患およびその他疾患の治療方法
JP6360025B2 (ja) 有機化合物
JP6038250B2 (ja) 有機化合物
JP5656874B2 (ja) Pde9阻害剤として使用されるアミノヘテロ環化合物
DE69611377T2 (de) 1,2,4-triazolo[1,5-c]pyrimidin-heterocyclische analoge mit antagonistischer aktivität auf dem adenosine a2a rezeptor
JP2002533464A (ja) プテリジン誘導体の免疫抑制作用
RU2007126570A (ru) Аминоимидазолоны, применяемые для ингибирования бета-секретазы
CN101448829A (zh) 4-氨基-吡啶并[3,2-e]吡嗪类,其作为磷酸二酯酶10的抑制剂的用途以及制备它们的方法
AU2008276455A1 (en) Combinations for the treatment of B-cell proliferative disorders
NO20055510L (no) 2-alkynyl- og 2-alkenylpyrazolo [4,3-E]-1,2,4-triazolo-[1,5-C]-pyrimidin-adenosin A2A-reseptorantagonister
JP2015536973A (ja) PDE4阻害剤とPI3δ阻害剤または二重PI3δ−γキナーゼ阻害剤とを含有する薬学的組成物
AU2008276451A1 (en) Treatments of B-cell proliferative disorders
JP2009533343A5 (cg-RX-API-DMAC7.html)
AR037680A1 (es) Antagonistas del receptor de adenosina a2a de 5-amino-pirazolo-[4,3-e]-1,2,4-triazolo[1,5-c]-pirimidinas sustituidas, composiciones farmaceuticas que los comprenden, el uso de dichos compuestos, solos o en combinacion para la elaboracion de un medicamento utiles para el tratamiento de enfermedades d
JP2013523889A5 (cg-RX-API-DMAC7.html)
JPH083041A (ja) ストレス関連障害治療剤
EA200800992A1 (ru) 2-амино-7,8-дигидро-6н-пиридо[4,3-d]пиримидин-5-оны, способ их получения, способ терапии с их помощью, компонент композиции и композиция на их основе, 2,4-диоксопиперидиновые соединения для их получения
JP4778894B2 (ja) 不安障害の治療方法
JP2025538452A (ja) 9型ホスホジエステラーゼの阻害による特定の神経精神障害の治療または予防におけるセロトニン作動性幻覚薬の効力の増強
JP2005503433A5 (cg-RX-API-DMAC7.html)
CA2490254A1 (en) Novel tetracyclic arylsulfonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them
Vu et al. Studies on adenosine A2A receptor antagonists: comparison of three core heterocycles
WO2006097263A3 (de) Kompatible solute enthaltende mittel zur oralen verwendung
US6051578A (en) Pyrazolopyrimidines for treatment of CNS disorders
JP2003519080A5 (cg-RX-API-DMAC7.html)